I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my original post that is linked.
Today's News:
1. cnbc.com/2020/07/07/novavax-sees-revenue-opportunities-from-potential-coronavirus-vaccine.html
2. fool.com/investing/2020/07/07/novavax-awarded-16-billion-from-operation-warp-spe.aspx
Today's News:
1. cnbc.com/2020/07/07/novavax-sees-revenue-opportunities-from-potential-coronavirus-vaccine.html
2. fool.com/investing/2020/07/07/novavax-awarded-16-billion-from-operation-warp-spe.aspx
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.